title: Antinociceptive and anti-hypernociceptive effects of Se-phenyl thiazolidine-4-carboselenoate in mice.
abstract: In this study, the antinociceptive, anti-hypernociceptive and toxic effects of orally administered (R)-Se-phenyl thiazolidine-4-carboselenoate (Se-PTC, 1-50 mg/kg) were evaluated in mice. Se-PTC did not change plasma aspartate (AST) and alanine aminotransferase (ALT) activities or urea and creatinine levels. Furthermore, in an open field test, Se-PTC did not alter the number of crossings and rearing. Se-PTC significantly reduced the amount of writhing when assessed by acetic acid-induced visceral nociception and attenuated the licking time of the injected paw in the early and late phases of a formalin test. In addition, Se-PTC reduced nociception produced by intra-plantar (i.pl.) injection of glutamate, capsaicin, cinnalmaldehyde, bradykinin, phorbol myristate acetate and 8-Bromo-cAMP. Se-PTC caused a significant increase in hot plate and tail-immersion response latencies, but the antinociceptive effect of Se-PTC in the tail immersion was not abolished by pretreatment with the non-selective opioid receptor antagonist, naloxone. Se-PTC (25 mg/kg) significantly inhibited nociceptive behavior induced by intrathecal (i.t.) injection of glutamate, N-methyl-D-aspartate (NMDA) and (±)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD), but failed to affect nociception induced by kainate and α-amino-3-hydroxy-5-mehtyl-4-isoxazolepropionic acid (AMPA). Mechanical hypernociception induced by carrageenan and Complete Freund's Adjuvant was attenuated by Se-PTC administration. These results indicate that Se-PTC produces antinociception in several models of nociception.
authors.affiliation: Universidade Federal do Pampa, BR 472, KM 582, Uruguaiana, CEP 97500-970, RS, Brazil.
authors.forename: Natasha Frasson
authors.initials: NF
authors.lastname: Pavin
authors.forename: Franciele
authors.initials: F
authors.lastname: Donato
authors.forename: Francielli Weber
authors.initials: FW
authors.lastname: Cibin
authors.forename: Cristiano Ricardo
authors.initials: CR
authors.lastname: Jesse
authors.forename: Paulo Henrique
authors.initials: PH
authors.lastname: Schneider
authors.forename: Helena Domingues
authors.initials: HD
authors.lastname: de Salles
authors.forename: Liliana do Amaral
authors.initials: Ldo A
authors.lastname: Soares
authors.forename: Diego
authors.initials: D
authors.lastname: Alves
authors.forename: Lucielli
authors.initials: L
authors.lastname: Savegnago
mesh_terms: D000700:Analgesics / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D018846:Excitatory Amino Acids / Q000378:metabolism; D005106:Exploratory Behavior / Q000187:drug effects; D006930:Hyperalgesia / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D059225:Nociception / Q000187:drug effects; D016566:Organoselenium Compounds / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D013696:Temperature; D053778:Thiazolidines / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity
chemical_list: D000700:Analgesics; D018846:Excitatory Amino Acids; D016566:Organoselenium Compounds; C568847:Se-phenyl thiazolidine-4-carboselenoate; D053778:Thiazolidines